Is Schizoaffective Disorder Still a Neglected Condition in the Scientific Literature?

Murru, Andréa; Pacchiarotti, Isabella; Nivoli, Alessandra; Colom, Francesc; Vieta, Eduard

doi:10.1159/000338022

Cited by 12 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present article provides a systematic review of neuropsychological and neuroimaging data in schizoaffective disorder, a neglected and controversial condition . The reliability and long‐term stability of schizoaffective disorder have proven to be high, and therefore a thorough review of its nosologic validity from the neuropsychological and neuroimaging standpoint is fully justified.…”

Section: Discussionmentioning

confidence: 99%

Neuropsychological and neuroimaging underpinnings of schizoaffective disorder: a systematic review

Madre

Canales‐Rodríguez

Ortíz-Gil³

et al. 2016

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Neuropsychological and neuroimaging underpinnings of schizoaffective disorder: a systematic review

Madre

Canales‐Rodríguez

Ortíz-Gil³

et al. 2016

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…It should be mentioned that most of the research concerns pure and classic BD-I patients, although there are some rare data concerning special populations such as BD-II [ 36 , 62 ], schizoaffective disorder [ 101 , 102 ], patients with high suicide risk [ 85 , 103 , 104 ] and patients with comorbid substance abuse [ 105 , 106 ].…”

Section: Discussionmentioning

confidence: 99%

Psychosocial treatment and interventions for bipolar disorder: a systematic review

et al. 2015

View full text Add to dashboard Cite

BackgroundBipolar disorder (BD) is a chronic disorder with a high relapse rate, significant general disability and burden and with a psychosocial impairment that often persists despite pharmacotherapy. This indicates the need for effective and affordable adjunctive psychosocial interventions, tailored to the individual patient. Several psychotherapeutic techniques have tried to fill this gap, but which intervention is suitable for each patient remains unknown and it depends on the phase of the illness.MethodsThe papers were located with searches in PubMed/MEDLINE through May 1st 2015 with a combination of key words. The review followed the recommendations of the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses statement.ResultsThe search returned 7,332 papers; after the deletion of duplicates, 6,124 remained and eventually 78 were included for the analysis. The literature supports the usefulness only of psychoeducation for the relapse prevention of mood episodes and only in a selected subgroup of patients at an early stage of the disease who have very good, if not complete remission, of the acute episode. Cognitive-behavioural therapy and interpersonal and social rhythms therapy could have some beneficial effect during the acute phase, but more data are needed. Mindfulness interventions could only decrease anxiety, while interventions to improve neurocognition seem to be rather ineffective. Family intervention seems to have benefits mainly for caregivers, but it is uncertain whether they have an effect on patient outcomes.ConclusionThe current review suggests that the literature supports the usefulness only of specific psychosocial interventions targeting specific aspects of BD in selected subgroups of patients.

show abstract

“…A recent study reports that in the last 2 decades over 5,300 studies related to psychiatric conditions (bipolar disorder, schizophrenia, schizoaffective disorder) were published, of which ~1 % related to schizoaffective disorder [57]. Our study findings indicate that a considerable number of Medicaid enrollees had a schizoaffective disorder-related inpatient admission during the study period.…”

Section: Discussionmentioning

confidence: 50%

Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder

Karve

Markowitz

et al. 2014

Appl Health Econ Health Policy

View full text Add to dashboard Cite

BackgroundHospital-discharged patients with schizoaffective disorder have a high risk of re-hospitalization. However, limited data exist evaluating critical post-discharge periods during which the risk of re-hospitalization is significant.ObjectiveAmong hospital-discharged patients with schizoaffective disorder, we assessed pharmacotherapy adherence and healthcare utilization and costs during sequential 60-day clinical periods before schizoaffective disorder-related hospitalization and post-hospital discharge.MethodsFrom the MarketScan® Medicaid database (2004–2008), we identified patients (≥18 years) with a schizoaffective disorder-related inpatient admission. Study measures including medication adherence and healthcare utilization and costs were assessed during sequential preadmission and post-discharge periods. We conducted univariate and multivariable regression analyses to compare schizoaffective disorder-related and all-cause healthcare utilization and costs (in 2010 US dollars) between each adjacent 60-day post-discharge periods. No adjustment was made for multiplicity.ResultsWe identified 1,193 hospital-discharged patients with a mean age of 41 years. The mean medication adherence rate was 46 % during the 60-day period prior to index inpatient admission, which improved to 80 % during the 60-day post-discharge period. Following hospital discharge, schizoaffective disorder-related healthcare costs were significantly greater during the initial 60-day period compared with the 61- to 120-day post-discharge period (mean US$2,370 vs US$1,765; p < 0.001), with rehospitalization (36 %) and pharmacy (40 %) accounting for over three-fourths of the initial 60-day period costs. Compared with the initial 60-day post-discharge period, both all-cause and schizoaffective disorder-related costs declined during the 61- to 120-day post-discharge period and remained stable for the remaining post-discharge periods (days 121–365).ConclusionsWe observed considerably lower (46 %) adherence during 60 days prior to the inpatient admission; in comparison, adherence for the overall 6-month period was 8 % (54 %) higher. Our study findings suggest that both short-term (e.g., 60 days) and long-term (e.g., 6–12 months) medication adherence likely are important characteristics to examine among patients with schizoaffective disorder and help provide a more holistic view of patients’ adherence patterns. Furthermore, we observed a high rate of rehospitalization and greater healthcare costs during the initial 60-day period post-discharge among patients with schizoaffective disorder. Further research is required to better understand and manage transitional care after discharge (e.g., monitor adherence), which may help reduce the likelihood of rehospitalization and the associated downstream costs.Electronic supplementary materialThe online version of this article (doi:10.1007/s40258-014-0095-8) contains supplementary material, which is available to authorized users.

show abstract

Is Schizoaffective Disorder Still a Neglected Condition in the Scientific Literature?

Cited by 12 publications

References 21 publications

Neuropsychological and neuroimaging underpinnings of schizoaffective disorder: a systematic review

Neuropsychological and neuroimaging underpinnings of schizoaffective disorder: a systematic review

Psychosocial treatment and interventions for bipolar disorder: a systematic review

Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder

Contact Info

Product

Resources

About